ReviewMolecular metabolism2021
Review: Glucose-sensitive insulin.
Review in Molecular metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Association Between HbA1c Levels and Postpartum Depressive Symptoms: Insights from Edinburgh Postnatal Depression Scale Screening After Gestational Diabetes Mellitus.Journal of clinical medicine · 2026Article
- The Potential Target Value of ADP-Ribosylation Factor 6 in Insulin Secretion Regulation and the Treatment of Metabolic Disorders.Metabolites · 2026Review
- Interaction between Paracetamol Glucuronide and a Glucose-Sensitive Insulin Molecule (NNC2215): Increased Risk of Hypoglycemia.ACS pharmacology & translational science · 2026Article
- Free energy simulations on a biomimetic glucose receptor: understanding the selectivity of GluHUT.Chemical science · 2026Article
- Review
- Regulation and function of insulin and insulin-like growth factor receptor signalling.Nature reviews. Molecular cell biology · 2025Review
- Catechol-based chemistry for hypoglycemia-responsive delivery of zinc-glucagon via hydrogel-based microneedle patch technology.Nature communications · 2025Article
- Update on the Status of Glucose-Responsive Insulins.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.Current pharmaceutical biotechnology · 2025Review
- Article
- 100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future.Biomedicines · 2024Review
- Semisynthesis of A6-A11 lactam insulin.Journal of peptide science : an official publication of the European Peptide Society · 2024Article
- [Evolution of insulin therapy: past, present, future].Problemy endokrinologii · 2024Review
- Current Advances in Stimuli-Responsive Hydrogels as Smart Drug Delivery Carriers.Gels (Basel, Switzerland) · 2023Review
- In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins.ACS pharmacology & translational science · 2023Article
- Continuous Glucose Monitoring Enabled by Fluorescent Nanodiamond Boronic Hydrogel.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Celebration of a century of insulin therapy in children with type 1 diabetes.Archives of disease in childhood · 2023Review
- New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals.The Journal of clinical endocrinology and metabolism · 2022Review
- Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoglycemia, the condition of low blood sugar, is a common occurance in people with diabetes using insulin therapy. Protecting against hypoglycaemia by engineering an insulin preparation that can auto-adjust its biological activity to fluctuating blood glucose levels has been pursued since the 1970s, but despite numerous publications, no system that works well enough for practical use has reached clinical practise. SCOPE OF REVIEW: This review will summarise and scrutinise known approaches for producing glucose-sensitive insulin therapies. Notably, systems described in patent applications will be extensively covered, which has not been the case for earlier reviews of this area. MAJOR
conclusionsThe vast majority of published systems are not suitable for product development, but a few glucose-sensitive insulin concepts have recently reached clinical trials, and there is hope that glucose-sensitive insulin will become available to people with diabetes in the near future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.